Merit Medical Systems Inc - MMSI STOCK NEWS

Merit Medical Systems (NASDAQ: MMSI) has launched the ReSolve® Thoracostomy Tray, designed to support minimally invasive procedures for draining fluids or air from the chest. This tray organizes all necessary components for a thoracostomy, enhancing procedural efficiency and patient care. The urgency of thoracostomy procedures can be life-saving, especially in cases of traumatic injuries. The new tray represents a step forward in improving patient outcomes and simplifying physician tasks, reflecting Merit’s commitment to innovative healthcare solutions.

Merit Medical Systems, Inc. (NASDAQ: MMSI) announced that it will release its financial results for Q1 2022 on April 27, 2022, after market close. An investor conference call is scheduled for the same day at 5:00 p.m. Eastern, where interested parties can participate via domestic and international phone lines or through a live webcast on merit.com. Founded in 1987, Merit Medical specializes in proprietary disposable devices for interventional, diagnostic, and therapeutic procedures across various medical fields.

Merit Medical Systems has received FDA clearance for its new SCOUT Bx Delivery System, a wire-free breast localization solution that streamlines the biopsy process. This innovative technology allows for the placement of a tiny reflector during stereotactic or MRI-guided biopsies, eliminating the need for an additional office visit. Annually, over 300,000 women undergo breast cancer surgery, and the SCOUT Bx can enhance surgical precision. This system builds on Merit's established SCOUT technology, used in nearly 300,000 procedures globally, aiming to improve patient outcomes.

Merit Medical Systems, Inc. (NASDAQ: MMSI) has received FDA breakthrough device designation for its Embosphere® Microspheres for Genicular Artery Embolization (GAE) aimed at treating knee osteoarthritis. This designation accelerates the review process and enhances communication between the FDA and Merit, potentially leading to quicker market access. The Embosphere Microspheres, used in over 250,000 procedures, are recognized for their effectiveness in embolotherapy. Chairman and CEO Fred P. Lampropoulos emphasized the designation's role in expanding treatment options for patients.

Merit Medical Systems reported a strong Q4 2021, with revenue of $278.5 million, an increase of 7.9% year-over-year, and a 32% rise in GAAP EPS to $0.36. For FY21, the company achieved revenues of $1.075 billion, up 11.5%, and non-GAAP EPS of $2.37, a 43% increase. Noteworthy segments include a 18.6% revenue growth in Cardiovascular Peripheral Intervention. The company also projected a 4%-6% revenue increase for FY22. Merit's gross margin improved significantly, showcasing efficient cost management amidst inflationary pressures.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a manufacturer of disposable medical devices, will announce its financial results for Q4 and FY 2021 on February 24, 2022, after market close. The company will also provide guidance for FY 2022. An investor conference call is scheduled for the same day at 5:00 p.m. Eastern Time. Merit, established in 1987, has a global presence with over 6,700 employees and operates in various medical fields, including cardiology and oncology, serving hospitals worldwide.

Merit Medical Systems (NASDAQ: MMSI) reported Q3 2021 revenue of $267.0 million, a 9.4% increase from Q3 2020. The company achieved a GAAP EPS of $0.21, recovering from a loss of ($0.05) per share last year. Non-GAAP EPS rose to $0.52 from $0.42. The growth was fueled by strong sales in the Cardiovascular segment, particularly in Peripheral and Cardiac Interventions. Merit's non-GAAP gross margin improved to 49.1%, aided by operational efficiencies despite inflationary pressures. The company reaffirmed its full-year revenue growth guidance at 9%-10%.

Merit Medical Systems, Inc. (NASDAQ: MMSI) announced financial results for the quarter ending September 30, 2021, to be released after market close on October 28, 2021. The company will conduct a conference call for investors at 5:00 p.m. Eastern on the same day. Merit is known for its proprietary disposable devices used in various medical fields including cardiology and oncology, employing around 6,700 individuals worldwide with facilities in several countries.

The WRAPSODY FIRST Study revealed promising results for the WRAPSODY Endoprosthesis by Merit Medical Systems (MMSI), showing a 100% target lesion primary patency (TLPP) rate at 30 days and an 84.6% TLPP rate at 12 months among 46 subjects treated for arteriovenous access circuit stenosis. The study indicated a 65.9% access circuit primary patency (ACPP) rate at one year, supporting the device's safety and effectiveness. The company plans a large WAVE Study to further validate these results and pursue FDA approval.